209 related articles for article (PubMed ID: 32716700)
1. Postmarketing Safety of Vaccines Approved by the U.S. Food and Drug Administration : A Cohort Study.
Tau N; Yahav D; Shepshelovich D
Ann Intern Med; 2020 Sep; 173(6):445-449. PubMed ID: 32716700
[TBL] [Abstract][Full Text] [Related]
2. Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.
Shepshelovich D; Tibau A; Goldvaser H; Molto C; Ocana A; Seruga B; Amir E
J Clin Oncol; 2018 Jun; 36(18):1798-1804. PubMed ID: 29641296
[TBL] [Abstract][Full Text] [Related]
3. Twenty Years of Targeted and Biologic Immunomodulatory Drugs: Postmarketing Modifications of Drug Labels Approved by the US Food and Drug Administration.
Berman J; Yavne Y; Edel Y; Elkayam O; Furer V; Shepshelovich D
Mayo Clin Proc; 2022 Aug; 97(8):1512-1522. PubMed ID: 35933136
[TBL] [Abstract][Full Text] [Related]
4. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.
Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E
Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457
[TBL] [Abstract][Full Text] [Related]
5. Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies.
Gafter-Gvili A; Tibau A; Raanani P; Shepshelovich D
Acta Haematol; 2020; 143(1):73-77. PubMed ID: 31167178
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
[TBL] [Abstract][Full Text] [Related]
7. Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979-2015.
Gopal AD; Rathi VK; Teng CC; Del Priore L; Ross JS
Ophthalmology; 2017 Aug; 124(8):1237-1246. PubMed ID: 28501378
[TBL] [Abstract][Full Text] [Related]
8. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
Hwang TJ; Orenstein L; Kesselheim AS; Bourgeois FT
JAMA Pediatr; 2019 Jan; 173(1):68-74. PubMed ID: 30452498
[TBL] [Abstract][Full Text] [Related]
9. Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug Administration.
Croteau D; Pinnow E; Wu E; Muñoz M; Bulatao I; Dal Pan G
Drug Saf; 2022 Feb; 45(2):169-180. PubMed ID: 35113347
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Data Sources That Support US Food and Drug Administration Medical Devices Safety Communications.
Tau N; Shepshelovich D
JAMA Intern Med; 2020 Nov; 180(11):1420-1426. PubMed ID: 32986074
[TBL] [Abstract][Full Text] [Related]
11. Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study.
Botelho SF; Martins MA; Vieira LB; Reis AM
J Clin Pharmacol; 2017 Apr; 57(4):493-499. PubMed ID: 27568487
[TBL] [Abstract][Full Text] [Related]
12. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review.
Pease AM; Krumholz HM; Downing NS; Aminawung JA; Shah ND; Ross JS
BMJ; 2017 May; 357():j1680. PubMed ID: 28468750
[No Abstract] [Full Text] [Related]
13. Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
Kim J; Nair A; Keegan P; Beaver JA; Kluetz PG; Pazdur R; Chuk M; Blumenthal GM
Oncologist; 2020 Apr; 25(4):348-354. PubMed ID: 32297444
[TBL] [Abstract][Full Text] [Related]
14. Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018.
Fan M; Chan AYL; Yan VKC; Tong X; Lau LKW; Wan EYF; Tam EYT; Ip P; Lum TY; Wong ICK; Li X
Orphanet J Rare Dis; 2022 Jan; 17(1):3. PubMed ID: 34983612
[TBL] [Abstract][Full Text] [Related]
15. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.
Skydel JJ; Zhang AD; Dhruva SS; Ross JS; Wallach JD
Clin Trials; 2021 Aug; 18(4):488-499. PubMed ID: 33863236
[TBL] [Abstract][Full Text] [Related]
16. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.
Mostaghim SR; Gagne JJ; Kesselheim AS
BMJ; 2017 Sep; 358():j3837. PubMed ID: 28882831
[No Abstract] [Full Text] [Related]
17. Assessing the safety and effectiveness of devices after US Food and Drug Administration approval: FDA-mandated postapproval studies.
Reynolds IS; Rising JP; Coukell AJ; Paulson KH; Redberg RF
JAMA Intern Med; 2014 Nov; 174(11):1773-9. PubMed ID: 25265209
[TBL] [Abstract][Full Text] [Related]
18. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
[TBL] [Abstract][Full Text] [Related]
19. Drug Safety in Labeling for Pediatric Drug Development and Dose Selection in Submissions to the US Food and Drug Administration.
Kim C; Park K; McMahon AW; Green FG; Green DJ; Burckart GJ
J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S133-S140. PubMed ID: 34185899
[TBL] [Abstract][Full Text] [Related]
20. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
Wallach JD; Egilman AC; Dhruva SS; McCarthy ME; Miller JE; Woloshin S; Schwartz LM; Ross JS
BMJ; 2018 May; 361():k2031. PubMed ID: 29794072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
